Endomorphin-1 & Endomorphin-2

Benefits

About Endomorphin-1 & Endomorphin-2

Endomorphin-1 and Endomorphin-2 are a pair of endogenous opioid tetrapeptides discovered in 1997 by James Zadina and colleagues, isolated from bovine and human brain tissue. They are the first and only endogenous peptides identified with high affinity and extraordinary selectivity for the mu-opioid receptor (MOR). Before their discovery, endogenous ligands had been identified for delta (enkephalins) and kappa (dynorphins) opioid receptors, but the endogenous mu-receptor ligand remained elusive. Endomorphin-1 (EM-1; Tyr-Pro-Trp-Phe-NH2) and Endomorphin-2 (EM-2; Tyr-Pro-Phe-Phe-NH2) differ only at the third amino acid position — tryptophan in EM-1 versus phenylalanine in EM-2 — yet this single substitution produces distinct pharmacological profiles. EM-1 displays a binding affinity (Ki) of approximately 360 pM for the mu-receptor with 4,000-fold selectivity over delta and 15,000-fold over kappa receptors. EM-2 binds with a Ki of approximately 690 pM, showing 13,400-fold mu/delta selectivity and 7,600-fold mu/kappa selectivity, making it even more mu-selective than EM-1. Both peptides are C-terminally amidated, a modification critical for receptor binding and enzymatic stability. In the central nervous system, EM-1 is predominantly localized in the nucleus accumbens, cortex, amygdala, thalamus, hypothalamus, striatum, and dorsal root ganglia, while EM-2 is concentrated in the spinal cord and lower brainstem, suggesting complementary roles in supraspinal versus spinal pain modulation. In rodent antinociception assays, EM-1 is approximately 3-fold more potent than EM-2 in supraspinal (intracerebroventricular) administration, producing potent dose-dependent analgesia in both hot-plate and tail-flick tests that is fully reversed by naloxone. At the spinal level, EM-2 engages additional descending pathways involving dynorphin A and met-enkephalin, indicating a more complex analgesic mechanism than EM-1. Beyond pain, endomorphins modulate cardiovascular function (EM-2 produces hypotension and bradycardia via nucleus tractus solitarius activation), immune regulation (anti-inflammatory effects in both acute and chronic peripheral inflammation models), reward and motivation, stress responses, and neuroendocrine function. A major limitation of native endomorphins is their extremely rapid enzymatic degradation — plasma half-life is estimated at 2-8 minutes — primarily by dipeptidyl peptidase IV (DPP-IV) cleaving the Tyr-Pro bond. However, degradation in cerebrospinal fluid proceeds more slowly, requiring over 2 hours for complete inactivation. This instability has driven extensive medicinal chemistry efforts to create stabilized analogs. Modified endomorphin analogs incorporating D-amino acids, N-methylation, or lipid conjugation have achieved dramatically improved metabolic stability, blood-brain barrier penetration, and prolonged analgesia with reduced side effects compared to morphine in preclinical models. One such analog, CYT-1010 (a cyclized EM-1 derivative), completed a Phase I clinical trial demonstrating significant analgesia versus baseline in healthy volunteers with no observed respiratory depression. Preclinical evidence suggests endomorphin-based analogs may produce less tolerance, lower abuse liability, reduced respiratory depression, and less constipation compared to morphine at equianalgesic doses, positioning them as a potential next-generation opioid analgesic platform.

Who Should Consider Endomorphin-1 & Endomorphin-2

• Opioid receptor pharmacology and signaling researchers
• Pain neuroscience investigators studying endogenous analgesia pathways
• Medicinal chemists developing stabilized opioid peptide analogs
• Neuroscience researchers studying biased agonism at mu-opioid receptors
• Immunology researchers investigating opioid-immune interactions
• Cardiovascular researchers studying central autonomic regulation

How Endomorphin-1 & Endomorphin-2 Works

Endomorphin-1 and Endomorphin-2 exert their primary pharmacological effects through high-affinity, highly selective agonism at the mu-opioid receptor (MOR/OPRM1). EM-1 binds MOR with a Ki of ~360 pM, while EM-2 binds at ~690 pM — both with selectivities of thousands-fold over delta (DOR) and kappa (KOR) opioid receptors, making them the most mu-selective endogenous opioid ligands known. Upon binding, both peptides activate Gi/Go protein-coupled signaling cascades: (1) inhibition of adenylyl cyclase reducing cAMP production, (2) closure of voltage-gated N-type and P/Q-type calcium channels reducing presynaptic neurotransmitter release, and (3) activation of G protein-coupled inwardly rectifying potassium channels (GIRKs) causing neuronal hyperpolarization. The net effect at the cellular level is suppression of nociceptive neuronal excitability and synaptic transmission. Critically, EM-1 and EM-2 differ in their downstream signaling profiles. EM-2 acts as a biased agonist with preferential recruitment of beta-arrestin over G protein signaling compared to reference agonists like DAMGO. EM-2 shows lower operational efficacy for G protein-mediated responses in mature neurons, which may contribute to its reduced respiratory depression and tolerance profiles. At the systems level, EM-1 predominantly mediates supraspinal antinociception through MOR activation in the periaqueductal gray (PAG), rostral ventromedial medulla (RVM), and thalamus. EM-2 also engages descending pain inhibitory pathways that trigger spinal release of dynorphin A acting on kappa receptors and met-enkephalin acting on delta-2 receptors, creating a multi-receptor analgesic cascade. EM-2 immunoreactive fibers selectively appose serotonergic neurons in the RVM, linking endomorphin signaling to descending serotonergic pain modulation. Cardiovascular effects are mediated through MOR activation in the nucleus tractus solitarius (NTS), where EM-2 produces depressor and bradycardic responses via ionotropic glutamate receptor-dependent pathways. Immunomodulatory actions occur through MOR expressed on immune cells including macrophages and lymphocytes, where endomorphins suppress pro-inflammatory cytokine release and inhibit p38 MAPK signaling. Both endomorphins promote MOR internalization via beta-arrestin-2 recruitment, contributing to rapid receptor desensitization and the short duration of action observed in vivo.

What to Expect

Dosing Protocol

Note: Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) and Endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) are endogenous opioid tetrapeptides and the most selective mu-opioid receptor agonists identified in mammalian tissue. First described by Zadina et al. in 1997, they remain research-only compounds with no approved clinical applications. Their extremely short plasma half-life (minutes) severely limits therapeutic utility in native form, though stabilized analogs (e.g., CYT-1010) have entered early clinical testing. Both peptides are subject to rapid degradation by dipeptidyl peptidase IV (DPP-IV) and aminopeptidases. Dosing values shown are estimates based on preclinical intracerebroventricular and intrathecal rodent studies and should not be interpreted as human dosing guidance. These peptides carry opioid-class risks including respiratory depression, dependence, and tolerance development. Endomorphins are presented here strictly for academic and research reference.

How to Inject Endomorphin-1 & Endomorphin-2

FOR RESEARCH USE ONLY. Endomorphin-1 and Endomorphin-2 are reconstituted by adding bacteriostatic water to the lyophilized vial — gently swirl until fully dissolved, do not vortex. Both peptides are soluble in water. In preclinical research, administration routes have included intravenous, subcutaneous, intrathecal (spinal), and intracerebroventricular (supraspinal) injection. Peripheral routes (SC, IV) require substantially higher doses than central routes due to poor blood-brain barrier penetration and rapid plasma degradation by DPP-IV and aminopeptidases. Intracerebroventricular doses in rodent studies typically range from 1-30 nmol; intrathecal doses from 0.1-30 nmol. Duration of analgesia after a single dose is approximately 15-30 minutes due to the short half-life. All handling should follow institutional protocols for opioid peptide research. Emergency opioid reversal agents (naloxone) must be immediately accessible.

Cycling Protocol

Pharmacokinetics

Side Effects

As mu-opioid receptor agonists, endomorphin-1 and endomorphin-2 produce the expected spectrum of opioid side effects, though generally at reduced severity compared to morphine at equianalgesic doses in preclinical models. Respiratory depression is the most serious acute risk, though it appears dose-dependent and less pronounced than with morphine or DAMGO at equivalent analgesic doses. Sedation, reduced locomotor activity, and motor impairment are observed in animal models. Gastrointestinal effects include reduced motility and constipation, though stabilized analogs show less GI impact than morphine. Tolerance to analgesic effects develops with repeated administration, but onset appears slower than morphine-induced tolerance. Acute tolerance (desensitization) develops more rapidly than with DAMGO, correlating with short duration of action. Physical dependence can develop with chronic exposure, and naloxone-precipitated withdrawal symptoms occur in dependent animals. Cardiovascular effects include hypotension and bradycardia, particularly with EM-2, mediated through central autonomic nuclei. Urinary retention and miosis are expected class effects. The extremely short half-life of native endomorphins limits the duration of both therapeutic and adverse effects. CAUTION: Despite a potentially improved safety profile relative to traditional opioids, endomorphins are mu-opioid agonists and carry inherent risks of respiratory depression, dependence, and addiction. Naloxone should be available as an emergency reversal agent in any research setting.

Contraindications

Drug Interactions

Storage & Stability

Molecular Profile

Related Peptides

Dermorphin

Healing & Recovery

BPC-157

Healing & Recovery

TB-500

Healing & Recovery

References

1. A potent and selective endogenous agonist for the mu-opiate receptorPubMed 9087409
2. Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous mu-opioid receptor agonistsReview
3. The endomorphin system and its evolving neurophysiological roleReview
4. Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphinePubMed 26748051
5. Dilemma of Addiction and Respiratory Depression in the Treatment of Pain: A Prototypical Endomorphin as a New ApproachReview
6. Endomorphin-1 and endomorphin-2 show differences in their activation of mu opioid receptor-regulated G proteins in supraspinal antinociception in micePubMed 10490881
7. Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mousePubMed 10640294
8. Endomorphins as agents for the treatment of chronic inflammatory diseasePubMed 16724864
9. Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphinePubMed 10988119
10. Activation and internalization of the mu-opioid receptor by the newly discovered endogenous agonists, endomorphin-1 and endomorphin-2PubMed 10218804